+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Verona Pharma plc - logo

Verona Pharma is a biopharmaceutical company that aims to improve the lives of those suffering from respiratory diseases by innovating therapeutic products. It was founded in 2005 in London, England. There proprietary lead candidate, RPL554 has opened a door to a whole new generation of drugs as it combines bronchodilator and an anti-inflammatory agent in a single compound. It has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma. Verona Pharma is listed on the NASDAQ global market and is supported by investors from U.S, U.K and Europe.

Asthma (Respiratory) - Drugs In Development, 2021 - Product Thumbnail Image

Asthma (Respiratory) - Drugs In Development, 2021

  • Report
  • August 2021
  • 931 Pages
From
From
From
From
From
From
From
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2022 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2022

  • Clinical Trials
  • February 2022
  • 195 Pages
From
From
From
Asthma - Pipeline Insight, 2022 - Product Thumbnail Image

Asthma - Pipeline Insight, 2022

  • Clinical Trials
  • March 2022
  • 100 Pages
From
From
Asthma - Pipeline Review, H2 2020 - Product Thumbnail Image

Asthma - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 811 Pages
From
From
Inhalable Drugs Market 2020-2026 - Product Thumbnail Image

Inhalable Drugs Market 2020-2026

  • Report
  • February 2020
From
Cystic Fibrosis - Pipeline Insight, 2022 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Insight, 2022

  • Drug Pipelines
  • March 2022
  • 100 Pages
From
Loading Indicator